24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)

被引：0
作者：
Mease, PJ
Choy, EHS
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Weinberg, MA
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ London Kings Coll, London WC2R 2LS, England
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Erasme Univ Hosp, B-1070 Brussels, Belgium
[7] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
RHEUMATOLOGY | 2005年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP5
引用
收藏
页码：I3 / I3
页数：1
相关论文
共 50 条
  • [41] MULTICENTER 24-WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF TACROLIMUS IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS
    Hur, J.
    Hong, S.
    Kim, S.
    Kim, G.
    Choi, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1404 - 1404
  • [42] Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes
    Edwards, C. J.
    Bradley, A.
    Nassab, M. H.
    Moller, B.
    Machold, K. P.
    Sapin, C.
    Ranza, R.
    Liu-Leage, S.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
  • [43] TOCILIZUMAB MONOTHERAPY COMPARED WITH ADALIMUMAB MONOTHERAPY IN RA: RESULTS OF A 24-WEEK STUDY
    Kavanaugh, Arthur
    Emery, Paul
    van Vollenhoven, Ronald F.
    Dikranian, SAra H.
    Alten, Rieke
    Klearman, Micki
    Musselman, David
    Agarwal, Sunil
    Green, Jennifer
    Gabay, Cem
    RHEUMATOLOGY, 2013, 52 : 45 - 45
  • [44] IXEKIZUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES
    Chaudhury, Koyel
    Bradley, Andrew
    Nassab, Mani Haschemi
    Moeller, Burkhard
    Machold, Klaus P.
    Sapin, Christophe
    Ranza, Roberto
    Leage, Soyi Liu
    Nash, Peter
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 33 - 34
  • [45] Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 24-week randomized, placebo-controlled trial (ASSERT)
    van der Heijde, D
    Dijkmans, B
    Geusens, P
    Sieper, J
    DeWoody, K
    Williamson, R
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 403 - 403
  • [46] Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and-2 trials
    McInnes, Iain
    Mease, Philip
    Hjuler, Kasper Fjellhaugen
    Raymond, Kyle
    Helliwell, Philip
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB28 - AB28
  • [47] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY
    D'agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 136 - 137
  • [48] Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study
    Napolitano, Maddalena
    Costa, Luisa
    Caso, Francesco
    Megna, Matteo
    Scarpa, Raffaele
    Balato, Nicola
    Ayala, Fabio
    Balato, Anna
    CLINICAL RHEUMATOLOGY, 2017, 36 (07) : 1589 - 1593
  • [49] Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study
    Maddalena Napolitano
    Luisa Costa
    Francesco Caso
    Matteo Megna
    Raffaele Scarpa
    Nicola Balato
    Fabio Ayala
    Anna Balato
    Clinical Rheumatology, 2017, 36 : 1589 - 1593
  • [50] EFFECT OF SECUKINUMAB ON SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS OF A 24-WEEK MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    McInnes, Iain
    Sieper, Joachim
    Braun, Juergen
    Emery, Paul
    van der Heijde, Desiree
    Isaacs, John
    Dahmen, Georg
    Wollenhaupt, Juergen
    Schulze-Koops, Hendrik
    Gsteiger, Sandro
    Bertolino, Arthur
    Hueber, Wolfgang
    Tak, Paul P.
    RHEUMATOLOGY, 2012, 51 : 90 - 91
12345